InnoCare Pharma (HKEX: 09969), a China-based commercial stage biopharmaceutical company, announced on Sunday that it has received Investigational New Drug (IND) approval for a clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, the firm's third innovative drug intended to treat autoimmune diseases to enter the clinical stage, in China.
The product is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor. It binds the JH2 domain, blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and inflammatory diseases. It will be developed to treat autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).
Dr Jasmine Cui, InnoCare co-founder, chairwoman and CEO said, 'There is a large unmet clinical need for the treatment of autoimmune diseases worldwide. InnoCare has built a strong pipeline in autoimmune diseases. With the approval of ICP-488 for clinical trials, InnoCare will further strengthen its autoimmune disease pipeline and provide better treatment options for patients with autoimmune diseases worldwide.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca